Gilead Sciences Inc

GILD is in Stage 3 distribution with a bearish medium-term bias. Price is forming successive lower highs and lower lows below the declining 9/20 EMAs, signaling continued seller control. Short-term momentum confirms execution readiness, so selling into the dynamic resistance around the 9/20 EMA cluster (~144.90–146.45) is appropriate. Key support lies near 138.10, while the long-term uptrend remains intact but is currently overshadowed by the bearish structure.

• ↑Q2 product sales rose 10% YoY to $7.6B, driven by HIV portfolio
• ↑HIV sales up 12% to $5.7B, boosted by FDA approval of Bixlenvo
• ↓Operating margin stood at –94% in Q2, driven by major acquisition expenses